feedback

Course Director

Ezra Cohen, MD, FRCPSC, FASCO
Ezra Cohen, MD, FRCPSC, FASCO

UC San Diego Health
San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Faculty

Barbara Burtness
Barbara Burtness, MD

Yale University School of Medicine
Yale Cancer Center
New Haven, Connecticut

Andrew Sharabi
Andrew Sharabi, MD, PhD

UC San Diego Health
San Diego Center for Precision Immunotherapy
Department of Radiation Medicine and Applied Sciences
UC San Diego Moores Cancer Center
La Jolla, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.5 Credits
Release Date:2019-Jul-02
Expiration Date:2020-Jul-01
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Already a cornerstone of care for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), immune checkpoint inhibitors are being explored in earlier treatment settings and in combination with other pillars of SCCHN care (such as surgery and radiotherapy). In this MasterClass activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 ASCO Annual Meeting, experts in head and neck (HNC) explore the evidence that is redefining the role of immunotherapy in HNC and offer insight on applications of new evidence on immunotherapy in HNC, as well as its future as a part of multimodal treatment plans. This activity also features a dedicated “Tumor Board” session designed to provide useful guidance on integrating checkpoint inhibitors into care—from the selection of upfront immunotherapy to the role of clinical trials as options for patients eligible for immune treatment.

Upon completion of this activity, participants will be able to:
  • Summarize evidence on the use of immune checkpoint inhibitors as single agents or in combination with other strategies in recurrent/metastatic, locally advanced, or resectable squamous cell carcinoma of the head and neck
  • Integrate immune checkpoint inhibitors into the treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck, including as upfront treatment or after progression on platinum chemotherapy
  • Identify patients with head and neck cancer who are eligible to receive immunotherapy as part of multimodal care across the disease spectrum, including in the context of a clinical trial
  • Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of head and neck cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 02, 2019 - July 01, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

Course Director

Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
UC San Diego Health
Co-director, San Diego Center for Precision Immunotherapy
Associate Director for Translational Science
UC San Diego Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
Co-director, Head and Neck Cancer Center of Excellence
La Jolla, California

Ezra Cohen, MD, FRCPSC, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Incyte Corporation; Merck & Co., Inc.; and Merck Sharp & Dohme.

Ezra Cohen, MD, FRCPSC, FASCO, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multimodal care of patients with resectable, locally advanced or previously untreated recurrent/metastatic squamous cell carcinoma of the head and neck.

Faculty

Barbara Burtness, MD
Professor of Medicine
Yale University School of Medicine
Co-Leader, Developmental Therapeutics Program
Yale Cancer Center
New Haven, Connecticut

Barbara Burtness, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aduro Biotech; Alligator Bioscience AB; AstraZeneca; Bayer; Bristol Myers Squibb; Celgene Corporation; Cue Biopharma; GlaxoSmithKline; and Maverick Therapeutics.
Other Financial or Material Support from Data Safety Monitoring Board for Medimmune and Speaker, Steering Committee for Merck & Co., Inc.

Barbara Burtness, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multimodal care of patients with resectable, locally advanced or previously untreated recurrent/metastatic squamous cell carcinoma of the head and neck.

Andrew Sharabi, MD, PhD
Assistant Professor of Radiation Medicine
Director, Radiation Medicine Core Facility
Department of Radiation Medicine and Applied Sciences
UC San Diego Health
Scientific Advisor, San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Andrew Sharabi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from Pfizer and Varian Medical Systems.
Other Financial or Material Support from Founder of Toragen, Inc.

Andrew Sharabi, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multimodal care of patients with resectable, locally advanced or previously untreated recurrent/metastatic squamous cell carcinoma of the head and neck.

Content Reviewers

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Pamela Ash, RN, MSN, CBCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).

Providership


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from Merck & Co., Inc.

Collaborative Partner


This activity was developed in collaboration with the Head and Neck Cancer Alliance (HNCA).

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.